This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thorpe, P. E. Articles by Blakey, D. C. Search for Related Content PubMed PubMed Citation Articles by Thorpe, P. E. Articles by Blakey, D. C.

New Coupling Agents for the Synthesis of Immunotoxins Containing a Hindered Disulfide Bond with Improved Stability in Vivo

Drug Targeting Laboratory, Imperial Cancer Research Fund, P. O. Box 123, Lincoln's Inn Fields, London WC2A 3PX, England

Two new coupling agents were synthesized for making immunotoxins containing disulfide bonds with improved stability in vivo: sodium S-4-succinimidyloxycarbonyl--methyl benzyl thiosulfate (SMBT) and 4-succinimidyloxycarbonyl--methyl-(2-pyridyldithio)toluene (SMPT). Both reagents generate the same hindered disulfide linkage in which a methyl group and a benzene ring are attached to the carbon atom adjacent to the disulfide bond and protect it from attack by thiolate anions.

An immunotoxin consisting of monoclonal anti-Thy-1.1 antibody (OX7) linked by means of the SMPT reagent to chemically deglycosylated ricin A-chain had better stability in vivo than an immunotoxin prepared with 2-iminothiolane hydrochloride (2IT) which generates an unhindered disulfide linkage. About 48 h after i.v. injection into mice, one-half of the SMPT-linked immunotoxin present in the blood was in intact form and one-half as released free antibody, whereas equivalent breakdown of the 2IT-linked immunotoxin was seen at about 8 h after injection. Consequently, the blood levels of the SMPT-linked immunotoxin remained higher than those of the 2IT-linked immunotoxin despite loss of immunotoxin from the blood by other mechanisms. Forty-eight h after injection, 10% of the injected dose of the SMPT-linked immunotoxin remained in the bloodstream as compared with only 1.5% of the 2IT-linked immunotoxin.

The ability of immunotoxins prepared with the new reagents to inhibit protein synthesis by Thy-1.1-expressing AKR-A/2 lymphoma cells in vitro was identical to that of immunotoxins prepared with 2IT or N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP). Clonogenic assays showed that fewer than 0.01% of AKR-A/2 cells survived exposure to high concentrations of OX7-abrin A-chain immunotoxins prepared with SMBT, 2IT, or SPDP. Twelve clones of cells which had survived treatment with the SMBT-linked immunotoxin were isolated. None of the clones was selectively resistant to the SMBT-linked immunotoxin when retested in cytotoxicity assays.

In conclusion, immunotoxins prepared with the new coupling agents should have improved antitumor activity in vivo because they are longer lived and do not break down so readily to release free antibody which could compete for the target antigens.

¹ To whom requests for reprints should be addressed.

Received 5/11/87. Revised 8/21/87. Accepted 8/24/87.

This article has been cited by other articles:

				B.-R. Wei, M.-A. Ghetie, and E. S. Vitetta The Combined Use of an Immunotoxin and a Radioimmunoconjugate to Treat Disseminated Human B-Cell Lymphoma in Immunodeficient Mice Clin. Cancer Res., February 1, 2000; 6(2): 631 - 642. [Abstract] [Full Text]

				M W J d. Brok, G C de Gast, J H M Schellens, and J H Beijnen Targeted toxins Journal of Oncology Pharmacy Practice, December 1, 1999; 5(4): 149 - 165. [Abstract] [PDF]

				C. McCoig, G. Van Dyke, C.-S. Chou, L. J. Picker, O. Ramilo, and E. S. Vitetta An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro PNAS, September 28, 1999; 96(20): 11482 - 11485. [Abstract] [Full Text] [PDF]

				D. Montagna, E. Yvon, V. Calcaterra, P. Comoli, F. Locatelli, R. Maccario, A. Fisher, and M. Cavazzana-Calvo Depletion of Alloreactive T Cells by a Specific Anti-Interleukin-2 Receptor p55 Chain Immunotoxin Does Not Impair In Vitro Antileukemia and Antiviral Activity Blood, May 15, 1999; 93(10): 3550 - 3557. [Abstract] [Full Text] [PDF]

				F. Matsuno, Y. Haruta, M. Kondo, H. Tsai, M. Barcos, and B. K. Seon Induction of Lasting Complete Regression of Preformed Distinct Solid Tumors by Targeting the Tumor Vasculature Using Two New Anti-Endoglin Monoclonal Antibodies Clin. Cancer Res., February 1, 1999; 5(2): 371 - 382. [Abstract] [Full Text] [PDF]

				P. Trail, D Willner, S. Lasch, A. Henderson, S Hofstead, A. Casazza, R. Firestone, I Hellstrom, and K. Hellstrom Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates Science, July 9, 1993; 261(5118): 212 - 215. [Abstract] [PDF]